Key facts
- This page summarizes Raul R. Rodriguez's Form 4 filing for RIGEL PHARMACEUTICALS INC (RIGL).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 03 Sep 2026, 18:59.
Raul R. Rodriguez - 01 Sep 2026 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)
- Reporting relationship
- CEO, President, Director
- Issuer ticker
- RIGL
- Reported as of
- 01 Sep 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Sep 2026, 18:59:51 UTC
- Prior SEC filing
- 22 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Raymond Furey (Attorney-in-Fact)
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Raul R. Rodriguez filed Form 4 for RIGEL PHARMACEUTICALS INC (RIGL) on 03 Sep 2026.
Change
- Previous filing in this sequence was filed on 22 Jun 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001190279
Primary reporting owner
RODRIGUEZ RAUL R
- Relationship
- CEO, President, Director
- Address
- RIGEL PHARMACEUTICALS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO
- Signature
- /s/ Raymond Furey (Attorney-in-Fact)
- Signature date
- 03 Sep 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RIGL
transaction
Common Stock
Tax liability
- Transaction value
- Shares
- -2,424
- Change %
- -0.88%
- Price
- $47.50*
- Shares after
- 273,362
- Date
- 01 Sep 2026
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Reflects the return to the Issuer of 3,807 shares previously reported as acquired under the Issuer's employee stock purchase plan.